US2023212303A1PendingUtilityA1

Antigen binding molecules with increased fc receptor binding affinity and effector function

Assignee: ROCHE GLYCART AGPriority: Nov 5, 2003Filed: Aug 24, 2022Published: Jul 6, 2023
Est. expiryNov 5, 2023(expired)· nominal 20-yr term from priority
C07K 16/2887C07K 2317/565C07K 2317/24C07K 16/28A61K 39/395A61P 35/00A61P 37/00C12N 5/10C12N 15/63A61K 2039/505C07K 2317/41C07K 2317/52C07K 2317/53C07K 2317/56C07K 2317/567C07K 2317/72C07K 2317/732C07K 2317/734C07K 2317/92Y10S530/808Y10S530/866Y10S530/867C12N 9/1051C12Y 204/01144A61P 1/04A61P 1/16A61P 11/00A61P 11/06A61P 13/12A61P 17/00A61P 17/02A61P 17/06A61P 19/02A61P 21/00A61P 21/04A61P 25/00A61P 25/14A61P 25/18A61P 27/02A61P 29/00A61P 31/06A61P 35/02A61P 37/02A61P 37/06A61P 37/08A61P 43/00A61P 5/00A61P 5/14A61P 5/40A61P 7/02A61P 7/04A61P 7/06A61P 9/00A61P 9/10A61P 3/10C07K 16/18C07K 2317/21C07K 2317/73C07K 2317/14C12N 15/11C07K 2319/01
81
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.

Claims

exact text as granted — not AI-modified
1 . An isolated polynucleotide comprising
 a. a sequence selected from the group consisting of: SEQ ID NO:5, SEQ ID NO.: 6 and SEQ ID NO: 7; and   b. a sequence selected from the group consisting of SEQ ID NO: 21, SEQ ID NO: 22 and SEQ ID NO: 23; and   c. sequence ID NO: 24.   
     
     
         2 - 259 . (canceled)

Join the waitlist — get patent alerts

Track US2023212303A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.